"I hope the third phase will begin in a week," she said in an interview with the Rossiya 1 broadcaster.
According to Popova, all results that have been up to this point were very good, the safety of the vaccine has been proven, and it is also areactogenic, since there is no xenogenic protein in it.
Participants in the trials felt neither an increase in temperature nor any deterioration in health, Popova claimed.